Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | JAK1 | P23458 | 6/20 | 0.36 |
| ▸ | TYK2 | P29597 | 6/20 | 0.36 |
| ▸ | JAK3 | P52333 | 6/20 | 0.36 |
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24973989 | 1.00 | JAK2 (0.36) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL21502005 | 0.88 | JAK2 (0.37) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL24974345 | 0.85 | ACHE (0.37) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL1106841 | 0.82 | ACHE (0.41) | ACHE | |
| SCHEMBL24973991 | 0.79 | JAK2 (0.30) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21502007 | 0.79 | JAK2 (0.30) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL24973093 | 0.78 | JAK2 (0.32) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22057991 | 0.77 | JAK2 (0.38) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL19122852 | 0.77 | JAK2 (0.38) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL19121741 | 0.76 | JAK2 (0.40) | JAK2JAK1TYK2JAK3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | JAK2 1041/4885JAK1 835/4885TYK2 1405/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | JAK2 1041/4885JAK1 835/4885TYK2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.